Long-Acting Injectable HIV Regimen on Par With Daily Drugs
SEATTLE — People living with HIV who have maintained undetectable virus levels with daily oral treatment could safely ditch the pills and transition to a more convenient every 2-month injectable alternative — without sacrificing efficacy, researchers found. In the 12-month results of the SOLAR trial, switching to the injectable long-acting cabotegravir plus rilpivirine (Cabenuva) from […]